Anorexia Nervosa

2024 Outcomes Report demonstrates treatment helps clients get well and stay well, regardless of diagnosis or demographics MIAMI, Oct. 30, 2024 /PRNewswire/ -- A new study reveals that over 52% of individuals entering eating disorder treatment began at or above a normal weight, challenging common misconceptions that people must look underweight to require intervention. Although eating disorders are common, many individuals do not receive the help they need. However, data shows that treatment significantly improves recovery outcomes, helping clients stay well for longer. These important insights are part of the largest longitudinal study on eating disorder treatment outcomes, conducted by Monte Nido, one of the nation's leading eating disorder treatment providers. The study reviewed data from 12,000 participants, and results underscore that eating disorders affect people of all shapes and sizes, and that specialized, client-first programs can have lifesaving, long-lasting benefits. Clients Get Well, Stay Well The long-term impact of eating disorder treatment has proven to be an essential component of the healing process. According to the study: 91% of adults and 94% of adolescents restored weight when needed Clients treated by Monte Nido maintained treatment gains 6-months post-discharge: 81% remained significantly improved in ED symptoms 73% remained significantly improved in depression symptoms 71% remained significantly improved in symptoms of anxiety "We believe that recovery is possible for everyone, and our outcomes study demonstrates that treatment can be effective in helping those with eating disorders live the full life they so deserve," Cassie McLean, Chief Executive Officer of Monte Nido. Co-Occurring Diagnoses Are Common The study shows that 85% of all clients had a co-occurring diagnosis of a mood, anxiety or substance use disorder, obsessive compulsive disorder, and/or posttraumatic stress disorder. A co-occurring diagnosis is a significant marker of the complexity of life with an eating disorder. "By addressing both the eating disorder and co-occurring mental health conditions, providers open sustainable pathways for client's healing," McLean emphasized. 45% of adults and 35.4% of adolescents in residential treatment had PTSD These clients demonstrated significantly higher scores on all measures including measures of eating disorder psychopathology, major depression, anxiety disorders and quality of life These clients experience both clinically and statistically significant decreases in their symptoms from admission to discharge Clients who completed cognitive processing therapy (CPT) sessions showed a significant reduction in PCL-5 scores, dropping from an average of 52.6 to 29, which is below the threshold score of 33, meaning clients no longer met criteria for PTSD at the end of treatment. Eating Disorders Don't Discriminate Despite social and cultural expectations about how those with eating disorders appear, they can and do impact anyone, regardless of gender, sexuality, race, ethnicity, age, socio-economic background and size. Nearly 29 million Americans will experience an eating disorder in their lifetime, and very few will get the care they need, largely due to barriers created by discrimination and weight stigma. "This study has shed light on who is living with eating disorders, and that they are far more complex and diverse than our socially conditioned image of those living with an eating disorder," said McLean. "This data will help expand our cultural understanding of individuals that are struggling with a range of eating disorders, and hopefully help remove some of the stigma that so often goes hand-in-hand with a diagnosis." Size & Weight 52% of people entering treatment were at or above "normal" weight at admission according to the NIH body mass index (BMI) calculator Most clients who were diagnosed with other specified feeding or eating disorder (OSFED) have atypical anorexia nervosa Gender & Sexuality 36% of all clients identified as LGBTQIA+ 63% of LGBTQIA+ adults in residential treatment met criteria for PTSD, compared to 45% cisgender heterosexual adults Age 77.6% of adolescents in residential treatment (average age of 15) had a co-occurring diagnosis, such as a mood disorder, anxiety disorder, or PTSD. 38% reported that someone else in their family has struggled with an eating disorder or disordered eating 75% of these adolescents had their families that were either very or extremely involved in treatment as indicated by regular family therapy and consistent communication with the clinical team Data Shines a Light on ARFID and BED Findings also emphasize the commonality of two lesser-known eating disorders, avoidant/restrictive food intake disorder (ARFID) and binge eating disorder (BED) within the client population. This data is important as certain disorders, like BED, are often misunderstood and misdiagnosed due to an overreliance on BMI as a measure of health. This misconception can lead to inadequate treatment, and even unhelpful guidance from providers. Adults, with an average admission age of 32, had binge eating disorder for 20 years before receiving treatment at Monte Nido, and 14 years before seeking any form of treatment. Clients with BED got better on all measures in all levels of care ARFID, which is characterized by "selective behaviors" or disinterest in food, has historically been difficult to diagnose, explaining why it's sometimes considered a "new" eating disorder. This year, Monte Nido developed the first measuring tool of its kind to help inform ARFID treatment, the Food Flexibility Scale™, which illustrates the levels of food flexibility that clients achieve through treatment. By using the novel food flexibility scale that measures progress across various degrees of variety, volume, and exposure to different food settings, the study indicates significant growth over the course of treatment. Of clients treated for ARFID, 92% of clients reached adequate nutritional intake levels by the end of treatment. Flexible Treatment Modalities Increase Accessibility The study also highlights the importance of flexible treatment options in improving accessibility, particularly through expanded virtual programs. These options allow clients to receive care despite geographic, scheduling, or familial barriers. "Access to flexible, innovative treatment options, especially virtual programs, is a game-changer for clients who might otherwise forgo the care they need," said Molly Perlman, MD, MPH, CEDS-C, Chief Medical Officer of Monte Nido. "By removing obstacles, virtual treatment is transforming how and when individuals seek help, making care more adaptable to real-life demands." Regardless of being in-person or online, data shows that less-intensive but highly structured remote treatment facilitates meaningful recovery among clients. 88% of clients discharged from virtual treatment described their experience as good to excellent Clients discharging from virtual programs with Monte Nido rated their experience with program staff- including clinical directors, primary therapists, dieticians, recovery coaches, their psychiatric and medical providers as excellent on average For more information about Monte Nido or to read the complete study, click here. To inquire about treatment at one of the Monte Nido programs, please visit . About the Monte Nido 2024 Outcomes Report The 2024 Outcomes Report is based on analysis of outcomes from Monte Nido programs nationwide, spanning all levels of care and more than 12,000 clients. Clients who consented to participate in the research study completed a series of clinical questionnaires at select intervals: at admission, upon transfer to a new level of care, and upon discharge from a program. In addition, follow-up data was obtained from consenting clients at specified time points after discharge. About Monte Nido Monte Nido is a national mental health provider committed to eradicating eating disorders by offering industry-leading care to adults and adolescents of all genders in a healing environment. Our clinically comprehensive, research-backed treatment in inpatient, residential, and day and virtual treatment programs show exceptional outcomes. Our clients get well and stay well six months after treatment. Founded in 1996, our expert staff of eating disorder professionals deliver compassionate care, breakthrough outcomes, and long-term recovery for our clients. Monte Nido operates 50 programs and in 28 states virtually across our family of programs: Monte Nido, Monte Nido Walden, Monte Nido Rosewood, and Monte Nido Clementine. Contact: Hannah Miller L.C. Williams & Associates 312-565-3900 [email protected] SOURCE Monte Nido WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

LONDON--(BUSINESS WIRE)-- $CMPS #Biotech --Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter 2024 ending September 30, 2024, and provide an update on recent business developments, on October 31, 2024. The management team will host a conference call at 8:00 am ET (12:00 pm UK) on October 31, 2024. To access the call, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on the Compass Pathways website at: Third Quarter 2024 Financial Results The webcast will also be available on the Investors section of the Compass Pathways website. The webcast will be archived for 30 days. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are living with mental health challenges and who are not helped by existing standards of care. We are pioneering the development of a new model of psilocybin treatment, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has Breakthrough Therapy designation from the US Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD). We have commenced a phase 3 clinical program of COMP360 psilocybin treatment in TRD, the largest randomized, controlled, double-blind psilocybin treatment clinical program ever conducted. Previously, we completed a phase 2b study with top line data showing a statistically significant (p<0.001) and clinically relevant improvement in depressive symptom severity after three weeks for patients who received a single 25mg dose of COMP360 psilocybin with psychological support. We have completed an open label phase 2 study of COMP360 psilocybin treatment for post-traumatic stress disorder (PTSD), and we are currently conducting a phase 2 clinical study in anorexia nervosa. Compass is headquartered in London, UK, with offices in New York and San Francisco in the US. Our vision is a world of mental wellbeing. Availability of other information about Compass Pathways Investors and others should note that we communicate with our investors and the public using our website ( ), our investor relations website (ir.compasspathways.com), and on social media (LinkedIn), including but not limited to investor presentations and investor fact sheets, US Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in us to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include additional social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933. Contacts Enquiries Media: Sally Bain, sally.bain@compasspathways.com , + 1 781 458 0443 Investors: Stephen Schultz, stephen.schultz@compasspathways.com , +1 401 290 7324

NEW YORK--( BUSINESS WIRE )--The 34th Barometer from Sermo , an online physician and provider community and leader in healthcare insights, surveyed 430+ mental healthcare providers around the world, including psychiatrists, general practice physicians, and advanced practice providers, on their sentiments about psychedelic and dissociative drug treatments, finding that 94% would be open to integrating these treatments into their practices if legalized in their countries. Worldwide, there has been growing interest from industry, government, media, and patients in psychedelics for the treatment of mental health conditions. 89% of HCPs surveyed believe that psychedelic medicines have unique therapeutic potential compared to traditional medications in treating patients with significant mental health conditions, such as treatment-resistant depression, post-traumatic stress disorder, and anorexia nervosa. Existing Familiarity with Psychedelics: HCPs are keeping up with developing research about psychedelics for the treatment of mental health conditions. The majority of surveyed healthcare professionals (67%) were either moderately or extensively familiar with the current clinical research on psychedelic and dissociative drugs. Surveyed psychiatrists had more familiarity (71%) with clinical research than other specialties. Ketamine is the most well-known psychedelic and dissociative drug among surveyed HCPs, with 45% indicating they are extremely or very familiar with its use in treating mental health disorders. This is followed by MDMA at 29%, LSD at 26%, and psilocybin at 25%. According to one anonymous Sermo U.S. psychiatrist and survey respondent, “ Psychedelics may have potential significant benefits but they also carry significant risks. If we are to introduce them as psychiatric treatments there needs to be research on their safety and efficacy. They need to be regulated and safety measures need to be put into place. It's important that the right patients obtain benefit and that people do not abuse them. It's important that they be medically supervised to prevent just anyone from using them. Once enough research has been done, I see them integrating into psychiatric care like esketamine, with strict measures in place.” Potential Barriers & Practice Integration: If legalized, HCPs feel there are many barriers to integrating psychedelic and dissociative drug treatments into their practices. Healthcare professionals report needing clinical guidelines (80%), comprehensive training programs (78%), and guidance to legal considerations (60%). HCPs do not view psychedelic and dissociative drugs as a first-line treatment, with nearly half (45%) of surveyed HCPs citing lack of response to traditional treatments as key criteria to prescribe psychedelic and dissociative drugs to a patient. Patients are also open to the idea of psychedelic and dissociative drug treatments. 79% of those surveyed report that they noticed increasing patient interest in psychedelics as a treatment option. When asked why they felt patients are more open, the most common answer was a growing acceptance of alternative mental health treatments (64%) and increased media coverage of psychedelics (60%). Agreement with FDA Decisions Varies by Treatment: U.S. healthcare professionals aren’t always in agreement with the FDA's decisions. Despite the recent decision not to grant MDMA approval for the treatment of PTSD, 52% of HCPs believe an exception should be made for veterans, who have spent years lobbying for the drug, to receive the treatment. However, 73% agreed with the FDA’s decision to grant LSD-based medications breakthrough status for the treatment of generalized anxiety. Two U.S. states have already decriminalized psilocybin (magic mushrooms) creating easy access for residents to purchase, possess, and grow them. While many healthcare professionals are open to the future of psychedelics to treat mental health conditions, the majority (61%) do not feel patients should be able to readily access psilocybin without medical intervention for the purposes of treating depression, addiction, and PTSD. Eye on Ketamine: 52% of surveyed HCPs believe that ketamine is being prescribed “off-label” too often. Two-thirds (67%) of surveyed HCPs believe compounding pharmacies should not be allowed to distribute Ketamine. This survey was fielded August 28th- September 4th as the 34th edition of Sermo’s ongoing Barometer study. The survey included 431 psychiatrists, general practice physicians, and advanced practice providers who have treated a patient for a mental health condition in the last year from the U.S., Canada, Australia, Germany, Italy, Spain, France, and the UK. To explore more findings, visit: https://app.sermo.com/barometer About Sermo: Sermo is a fast, frictionless physician-first platform providing the healthcare industry with real-time business insights and authentic physician engagements through our global community of 1.5M healthcare professionals and state-of-the-art technology. For over 20 years, Sermo has been turning physician experience, expertise, and observations into actionable insights that benefit pharmaceutical companies, healthcare partners, and the medical community at large. To learn more, visit www.sermo.com .